RA Session II
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About RA Session II
RA Session II was last confirmed as Board Member at Taysha Gene Therapies, Inc. (TSHA) in a filing dated April 28, 2022. Earlier roles on record: CEO at Taysha Gene Therapies, Inc. (TSHA) until December 16, 2022. Taysha Gene Therapies, Inc. reported in an 8-K filed December 22, 2022 that RA Session II resigned as President and Chief Executive Officer, effective December 16, 2022. RA Session II has spoken on 6 earnings calls across 1 company, most recently for Taysha Gene Therapies, Inc. on November 8, 2022.
“On December 16, 2022, RA Session II, the President and Chief Executive Officer of Taysha Gene Therapies, Inc. (the "Company"), resigned from his operating role, effective immediately.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2022-04-28
Last confirmed by a filing; no departure on record
-
Start not stated–2022-12-16
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.